Genfit is the Lille-based biotech company that spent a decade pursuing one of pharmacology’s most commercially coveted but scientifically elusive targets — non-alcoholic steatohepatitis (NASH), a form of liver disease affecting 115 million people globally — and emerged, after a major clinical setback, with a pivot that produced Europe’s first approved treatment for primary biliary cholangitis (PBC) and a refocused pipeline that demonstrates France’s capacity to sustain biotech ambition through adversity.

The NASH Journey: Setback as Strategy

Genfit was founded in 1999 as a spinout from the Pasteur Institute of Lille, initially focused on nuclear receptor biology — the molecular switches that regulate fat and sugar metabolism in liver cells. Its scientific founder, Bart Staels, is one of Europe’s leading metabolic disease researchers.

Through the 2010s, Genfit built a NASH pipeline centered on elafibranor, a dual PPAR-α/δ agonist designed to reduce liver fat, inflammation, and fibrosis. NASH attracted more than billion in global pharmaceutical R&D investment between 2010 and 2020, with Genfit, Intercept Pharmaceuticals, Gilead, and Pfizer all running large Phase 3 trials.

In May 2020, Genfit announced that elafibranor had failed its primary endpoint in the RESOLVE-IT Phase 3 NASH trial: 18.3% of patients in the elafibranor arm met the primary composite endpoint (NASH resolution without worsening fibrosis) compared to 14.7% in the placebo arm — numerically higher, but not statistically significant (p=0.073, threshold p<0.05). The company’s stock fell 70% in a single session.

The failure was not unique to Genfit — Intercept’s obeticholic acid and Gilead’s selonsertib failed Phase 3 in NASH in the same period. The NASH field’s collective failure reflected the disease’s heterogeneity and the inadequacy of the regulatory endpoint (liver biopsy-defined resolution), not the futility of the target.

The Pivot: Elafibranor in Primary Biliary Cholangitis

Genfit’s critical insight was that while elafibranor failed the strict NASH endpoint, it had shown consistent effects on liver enzyme normalization and fibrosis markers — signals that were more clinically meaningful in a related but better-defined liver disease: primary biliary cholangitis (PBC).

PBC is a chronic autoimmune liver disease affecting approximately 400,000 patients in Europe and North America, with inadequate treatment options after first-line ursodeoxycholic acid. Genfit licensed elafibranor rights specifically for PBC to Ipsen (French pharmaceutical company) in 2021, in a deal worth up to €1.2 billion in milestones plus royalties — one of the largest biotech licensing deals in French history.

Elafibranor (Iqirvo) — EU Approval (2024)

The Phase 3 ELATIVE trial in PBC enrolled 161 patients and demonstrated a significant 51% alkaline phosphatase normalization rate for elafibranor versus 4% for placebo (p<0.001). The EMA granted conditional marketing authorization for Iqirvo (elafibranor, developed under Ipsen’s commercial branding) in March 2024 — the first EU approval for a new PBC mechanism since 2016.

Ipsen is responsible for commercialization; Genfit receives royalties on net sales. With a target patient population of approximately 100,000 treatable PBC patients in Europe, and pricing positioning in the €20,000-30,000 annual treatment range, Iqirvo represents Genfit’s first material royalty revenue stream — estimated at €15-25 million annually in near-term European royalties, scaling as US approval (filed with FDA in 2024) progresses.

Current Pipeline and France 2030 Support

With the Ipsen licensing deal providing both immediate capital and long-term royalty exposure, Genfit refocused its internal pipeline on:

NTZ (Nitazoxanide) — NASH/Liver Fibrosis: Nitazoxanide, an antiparasitic drug with liver anti-inflammatory properties, is Genfit’s lead internal NASH compound following elafibranor’s NASH program termination. An investigator-sponsored Phase 2 trial is underway at the University Hospital of Lille.

GNS (Genfit Nash Score): Genfit’s non-invasive NASH diagnostic — a serum biomarker panel that correlates with liver biopsy findings — is commercialized through Genfit’s diagnostics subsidiary. The GNS score addresses a critical market gap: liver biopsy-based NASH diagnosis is invasive, expensive, and unsuitable for population screening or trial enrollment. The diagnostic product generates approximately €3-5 million annually.

France 2030 support for Genfit comes through multiple channels:

• €8 million in i-Bio program grants (2022-2024) for NTZ development and diagnostic platform
• €4.5 million in CIR (Crédit d’Impôt Recherche) annual tax credits
• Hauts-de-France regional innovation funding: €3 million for Genfit’s Lille-area research facilities

The Lille Health Innovation Ecosystem

Genfit’s Lille headquarters situates it within the Hauts-de-France regional health cluster — France’s fourth-largest, anchored by the University Hospital of Lille (CHRU), the Pasteur Institute of Lille, and the Institut de Biologie de Lille. The Eurasanté health cluster in Loos (adjacent to Lille) houses 200+ health companies and 20+ research laboratories, with Genfit as one of its most prominent tenants.

France 2030 has invested €75 million in the Hauts-de-France health cluster through 2025, including a new clinical research infrastructure at the CHRU Lille and an expansion of the Eurasanté incubator. Genfit benefits directly through improved clinical trial access and talent pipeline.

Competitive Positioning Post-Elafibranor

The PBC approval and Ipsen royalties transform Genfit from a single-asset NASH bet into a diversified, commercially validated biotech with:

• Royalty stream from a marketed product (Iqirvo)
• Internal early-stage pipeline
• Diagnostic revenue generating operational cash flow
• Credibility with European and US institutional investors rebuilt through the PBC success

The key remaining question is whether Genfit can develop its next internal compound — NTZ for NASH — into a Phase 3-capable asset, or whether it pursues a business development strategy (licensing or partnership) to supplement its royalty economics with an additional commercial product.

Related: France 2030 Health Hub | OSE Immunotherapeutics | Clinical Trials in France | i-Bio Funding Program